Enliven Therapeutics, Inc. cotiza a 40.84 USD y tiene una capitalización bursátil de $3.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid l…
| Métrica | ELVN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -22.6% | -40.4% | +17.8% |
| ROA | -21.8% | -32.0% | +10.2% |
| Current Ratio | 28.66 | 2.84 | +25.82 |
| Debt / Equity | — | 0.28 | — |